 |
|
Virologic Outcomes of Complex Drug Regimens for Human Immunodeficiency Virus
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: Dr Hammer and colleagues1 reported that increasing to a more potent regimen (including 2 protease inhibitors [PIs] and efavirenz) improved virologic outcome at 24 weeks among patients with human immunodeficiency virus (HIV) who had not improved on a PI-based regimen. Despite these intensive, complex regimens (including up to 40 pills daily), only 47% of patients receiving 2 PIs and who were naive to efavirenz achieved an undetectable plasma HIV-RNA load. It would be helpful to know more about the factors, apart from regimen potency, that also contributed to successful therapy such as prior therapy, prior patient adherence, on-study tolerability, and on-study adherence. A potent but intolerable regimen is doomed to fail, especially for longer periods, as is the prescription of a complex regimen to a patient who has been unable to adhere to similar regimens in the past.2
The authors did not describe whether they enrolled patients . . . [Full Text of this Article]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure: A Randomized Trial
Scott M. Hammer, Florin Vaida, Kara K. Bennett, Mary K. Holohan, Lewis Sheiner, Joseph J. Eron, Lawrence Joseph Wheat, Ronald T. Mitsuyasu, Roy M. Gulick, Fred T. Valentine, Judith A. Aberg, Michael D. Rogers, Cheryl N. Karol, Alfred J. Saah, Ronald H. Lewis, Laura J. Bessen, Carol Brosgart, Victor DeGruttola, John W. Mellors, and for the AIDS Clinical Trials Group 398 Study Team
JAMA. 2002;288(2):169-180.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Diagnostic Errors--The Next Frontier for Patient Safety
Newman-Toker and Pronovost
JAMA 2009;301:1060-1062.
FULL TEXT
|
